Risk factors for Early onset of Proteinuria in Patients Receiving Atezolizumab Plus Bevacizumab for Unresectable Hepatocellular Carcinoma.
Conclusion
Our study found that controlling blood pressure is extremely important for the management of proteinuria in patients with HCC who are receiving Atezo+Bev. (Source: Liver Cancer)
Source: Liver Cancer - November 29, 2022 Category: Cancer & Oncology Source Type: research
IMbrave150: Efficacy and Safety of Atezolizumab Plus Bevacizumab vs Sorafenib in Patients With Barcelona Clinic Liver Cancer Stage B Unresectable Hepatocellular Carcinoma —An Exploratory Analysis of the Phase III Study
Conclusion: Efficacy benefits were observed with atezolizumab + bevacizumab in patients with baseline BCLC Stage B disease, consistent with the intention-to-treat population. (Source: Liver Cancer)
Source: Liver Cancer - November 28, 2022 Category: Cancer & Oncology Source Type: research
Tumor radiomic features on pretreatment MRI to predict response to lenvatinib plus an anti –PD-1 antibody in advanced hepatocellular carcinoma: a multicenter study
Introduction: Lenvatinib plus an anti –PD-1 antibody has shown promising anti-tumor effects in patients with advanced hepatocellular carcinoma (HCC), but with clinical benefit limited to a subset of patients. We developed and validated a radiomic-based model to predict objective response to this combination therapy in advanced HCC pat ients.
Methods: Patients (N = 170) who received first-line combination therapy with lenvatinib plus an anti–PD-1 antibody were retrospectively enrolled from 9 Chinese centers; 124 and 46 into the training and validation cohorts, respectively. Radiomic features were extracted from pretreat...
Source: Liver Cancer - November 28, 2022 Category: Cancer & Oncology Source Type: research
Low baseline CXCL9 predicts early progressive disease in unresectable HCC with atezolizumab plus bevacizumab treatment
Introduction: Atezolizumab plus bevacizumab treatment is highly effective in patients with unresectable hepatocellular carcinoma (HCC). However, progressive disease (PD) occurs in approximately 20% of HCC patients treated with atezolizumab plus bevacizumab, resulting in a poor prognosis. Thus, the prediction and early detection of HCC is crucial.
Methods: Patients with unresectable HCC treated with atezolizumab plus bevacizumab and had baseline preserved serum (n = 68) were screened and classified according to their PD, six weeks after treatment initiation (early PD; n = 13). Of these, four patients each with and without ...
Source: Liver Cancer - October 31, 2022 Category: Cancer & Oncology Source Type: research
Atezolizumab and bevacizumab combination therapy and sequential conversion hepatectomy for advanced fibrolamellar hepatocellular carcinoma presenting pseudoprogression
We report the first case of ABT for advanced FLHCC followed by hepatectomy presenting pseudoprogression of lymph node (LN) metastases which was pathologically proven after surgery.
The patient was a 30-year-old man with advanced FLHCC and multiple LN metastases behind the pancreatic head, and ABT was introduced. After four courses of treatment, CT indicated a minor decrease in the intratumor vascularity of the liver tumor. However, the size of metastatic LNs increased. Subsequently, the patient presented with bloody stool, and colonoscopy revealed immune-related colitis caused by atezolizumab. Therefore, the fifth course ...
Source: Liver Cancer - October 25, 2022 Category: Cancer & Oncology Source Type: research
Was Concurrent Antibiotic Use During Immunotherapy Associated with Higher Mortality for Patients with Advanced Hepatocellular Carcinoma?
(Source: Liver Cancer)
Source: Liver Cancer - October 10, 2022 Category: Cancer & Oncology Source Type: research
Regorafenib versus Cabozantinib as a Second-Line Treatment for Advanced Hepatocellular Carcinoma: An Anchored Matching-Adjusted Indirect Comparison of Efficacy and Safety
Conclusion: This indirect treatment comparison suggests, relative to cabozantinib, that regorafenib could be associated with favorable OS (not statistically significant), lower rates of dose reductions and discontinuation due to treatment-related AEs, and lower rates of severe diarrhea and fatigue. (Source: Liver Cancer)
Source: Liver Cancer - October 7, 2022 Category: Cancer & Oncology Source Type: research
Regorafenib vs. cabozantinib as second-line treatment for advanced hepatocellular carcinoma: an anchored matching-adjusted indirect comparison of efficacy and safety
Conclusion: This indirect treatment comparison suggests, relative to cabozantinib, regorafenib could be associated with favorable OS (not statistically significant), lower rates of dose reductions and disc ontinuation due to treatment-related AEs, and lower rates of severe diarrhea and fatigue. (Source: Liver Cancer)
Source: Liver Cancer - October 7, 2022 Category: Cancer & Oncology Source Type: research
PD-1/CTLA-4 blockade leads to expansion of CD8+PD-1int TILs and results in tumor remission in experimental liver cancer
Conclusion: In our model, few doses of checkpoint inhibitors during the priming of transferred CD8+ tumor-specific T cells were sufficient to induce tumor remission. PD-1/CTLA-4 blockade neither reinvigorated the effector function of CD8+PD-1high TILs nor changed the functionality of CD8+PD-1int TILs. Therefore, PD-1/CTLA-4 blockade has an ameliorative effect the expansion of recently primed CD8+ T cells while preventing their development into CD8+PD-1high TILs in the TME. This finding could have important implications for future T cell therapies . (Source: Liver Cancer)
Source: Liver Cancer - October 7, 2022 Category: Cancer & Oncology Source Type: research
Implications of the TACTICS Trial: Establishing the New Concept of Combination/Sequential Systemic Therapy and TACE to Achieve Synergistic Effects
NA (Source: Liver Cancer)
Source: Liver Cancer - October 6, 2022 Category: Cancer & Oncology Source Type: research
Surgical outcomes of laparoscopic versus open hepatectomy for left hepatocellular carcinoma: Propensity score analyses using retrospective Japanese and Korean individual patient data
Conclusions: LLH decreases the risk of tumor recurrence and improves OS in patients with primary HCC located in the left liver. (Source: Liver Cancer)
Source: Liver Cancer - October 5, 2022 Category: Cancer & Oncology Source Type: research
Erratum
Liver Cancer (Source: Liver Cancer)
Source: Liver Cancer - October 4, 2022 Category: Cancer & Oncology Source Type: research
Tislelizumab in Patients with Previously Treated Advanced Hepatocellular Carcinoma (RATIONALE-208): A Multicenter, Non-Randomized, Open-Label, Phase 2 Trial
Conclusion: Tislelizumab demonstrated durable objective responses, regardless of the number of prior lines of therapy, and acceptable tolerability in patients with previously treated advanced HCC. (Source: Liver Cancer)
Source: Liver Cancer - October 4, 2022 Category: Cancer & Oncology Source Type: research
